92% Oral Bioavailability
92%
Breakthrough vs. 1% industry standard (Digital Twins / Z-Score -102k).
Bioavailability ceiling broken
Exclusive licensing dossier
NCS-004: The 92% Bioavailability Breakthrough in Oral GLP-1
Overcoming the 1% absorption barrier of current compounds. Surgical-grade weight loss (15kg–30kg) in a scalable oral format.
Evidence Grid
A compressed technical snapshot designed for executive licensing review.
Institutional-grade validation
Proprietary 6-Step Green Synthesis Route
6-Step
High-yield, ESG-compliant manufacturing process, eliminating heavy metals and reducing solvent waste by 70%.
ESG-compliant manufacturing
$0.10 USD Manufacturing Cost
$0.10
Per dose. Industrial throughput designed for global scale.
Industrial scalability unlocked
High-Dimensional Fidelity: The NovaCore Systems Engine
Institutional-grade molecular architecture powered by symbolic processing.
NovaCore QVM Engine
At the core of our discovery process is the NovaCore QVM Engine. Unlike traditional stochastic models, our proprietary framework operates in high-dimensional vector spaces (up to 8192D), utilizing symbolic processing to navigate a state-space of massive complexity (1021+ states). This deterministic approach ensures unprecedented molecular precision and a 6-step green synthesis route, delivering industrial scalability where traditional R&D fails.
Market Comparison
A licensing-focused view of the measurable advantage versus the current injectable standard.
| Parameter | NCS-004 | Current Injectable Standard |
|---|---|---|
| Bioavailability | 92% oral bioavailability (Breakthrough vs. 1% industry standard) | Injection-dependent; oral formats historically ~1% absorption barrier |
| Patient Compliance | Oral regimen aligned with mass-market adherence | Needle fatigue; cold-chain and injection training burden |
| Scalability | $0.10 USD manufacturing cost per dose | Higher device + logistics cost; constrained throughput |
| Process & ESG | Proprietary 6-step green synthesis route (eliminates heavy metals; -70% solvent waste) | Higher solvent load; legacy process constraints |
Tip: swipe horizontally on mobile for full table visibility.
Urgency & Strategy
Time-sensitive positioning designed for a decisive licensing outcome.
IP Priority Established
January 2026 • Priority lock with structured global route
High-contrast positioning for strategic partners seeking rapid market entry: enforceable IP sequencing, clean licensing scope, and a compliance-first disclosure pathway.
180-Day Global Licensing Exit
-
Days 1–45 • Strategic Outreach & Mutual NDA ExecutionGate 01
Targeted outreach, mutual NDA execution, and controlled entry to the VDR.
-
Days 46–105 • Deep-Dive Technical Due Diligence & VDR AuditGate 02
Deep-dive technical diligence, replication review, and VDR audit.
-
Days 106–150 • Binding Offer Submission & Final NegotiationsGate 03
Binding offer submission, definitive terms, and final negotiations.
-
Days 151–180 • Asset Transfer, Escrow Closing & Global Licensing HandoverGate 04
Asset transfer, escrow closing, and global licensing handover.
Trust & Security
Technical logs, raw datasets, and replication artifacts are only released under a signed mutual NDA.
Controlled Disclosure Protocol
Access is compartmentalized by role and timestamp. Confidential materials are watermarked and recorded to preserve integrity across multi-party due diligence.